Blog
RSS FeedPosted by Michael Wonder on 22 Mar 2023
Nivolumab in combination with chemotherapy for the neo-adjuvant treatment of patients with resectable non-small-cell lung cancer
22 March 2023 - NICE has published evidence based recommendations on the use of nivolumab (Opdivo) in combination with chemotherapy ...
Posted by Michael Wonder on 08 Mar 2023
NICE recommended weight loss drug to be made available in specialist NHS services
8 March 2023 - Thousands of people will soon be able to be prescribed a drug to help them lose weight ...
Posted by Michael Wonder on 01 Mar 2023
Eight digitally enabled therapies to treat depression and anxiety in adults conditionally recommended by NICE
1 March 2023 - Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by ...
Posted by Michael Wonder on 01 Mar 2023
Eptinezumab for the prevention of migraine
1 March 2023 - The recommendation was made after consideration of the evidence submitted by Lundbeck, a review of this submission ...
Posted by Michael Wonder on 28 Feb 2023
Baricitinib for the treatment of patients with severe alopecia areata
28 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Feb 2023
Axicabtagene ciloleucel for the treatment of adults with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after two or more systemic therapies
28 February 2023 - This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access ...
Posted by Michael Wonder on 22 Feb 2023
Ataluren for the treatment of patients with Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
22 February 2023 - This guidance updates and replaces NICE highly specialised technologies guidance HST3 on the use of ataluren for ...
Posted by Michael Wonder on 22 Feb 2023
Ixazomib citrate and lenalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
22 February 2023 - This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access agreement ...
Posted by Michael Wonder on 17 Feb 2023
Teclistamab for the treatment of patients with relapsed or refractory multiple myeloma after three or more therapies
16 February 2023 - Another new cancer medicine becomes an assessment non-starter. ...
Posted by Michael Wonder on 15 Feb 2023
Vutrisiran for the treatment of patients with hereditary transthyretin-related amyloidosis
15 February 2023 - NICE has published final draft guidance on the use of vutrisiran for the treatment of adults ...
Posted by Michael Wonder on 09 Feb 2023
Digital mental health tech for children and young people recommended by NICE in first rapid healthtech guidance
8 February 2023 - Four digital technologies that can help children and young people with mild to moderate symptoms of anxiety ...
Posted by Michael Wonder on 09 Feb 2023
NICE recommends genetic test to prevent newborn babies going deaf
9 February 2023 - A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a ...
Posted by Michael Wonder on 08 Feb 2023
Nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy for patients with untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
8 February 2023 - Nivolumab, when used in combination with fluoropyrimidine-based and platinum-based combination chemotherapy, is recommended as an option ...
Posted by Michael Wonder on 01 Feb 2023
Nintedanib esylate for the treatment of adults with idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
1 February 2023 - Nintedanib esylate is recommended as an option for the treatment of adults with idiopathic pulmonary fibrosis ...
Posted by Michael Wonder on 01 Feb 2023
Somatrogon for treating growth disturbance in people 3 years and over
1 February 2023 - Somatrogon is recommended as an option for the treatment of children 3 years of age and over ...